Quarterly ResultJul 30, 2026, 07:32 AM
Wave Life Sciences Q2 Update: WVE-006 FDA Meeting, WVE-007 Phase 2a
AI Summary
Wave Life Sciences reported its second-quarter 2026 financial results and provided a business update, highlighting significant progress in its clinical pipeline. Dosing has begun in the Phase 2a multidose portion of the INLIGHT trial for WVE-007 in obesity, with Phase 2 combination trials expected to start in 2H 2026. The company has an FDA meeting scheduled for late summer 2026 to discuss an accelerated approval pathway for WVE-006 for AATD, supported by RestorAATion-2 data. Wave also reported $490.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing a cash runway into Q3 2028, despite increased net losses.
Key Highlights
- Cash, cash equivalents, marketable securities: $490.6 million as of June 30, 2026.
- Expected cash runway: Into Q3 2028.
- Q2 2026 Revenue: $2.3 million, down from $8.7 million in Q2 2025.
- Q2 2026 Net Loss: $69.4 million, up from $50.5 million in Q2 2025.
- WVE-007 Phase 2a dosing underway for obesity (BMI 35-50 kg/m2).
- FDA meeting for WVE-006 accelerated approval pathway by end of summer 2026.
- CTA submission for WVE-008 on track for 2H 2026.
- WVE-007 Phase 2 combination trials on track for 2H 2026.
Price Impact
More from WVE